The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 25155913 |
32 |
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa. |
Astrazeneca |
| 23200256 |
54 |
Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor. |
Astrazeneca |
| 21824780 |
71 |
Discovery of a novel series of selective HCN1 blockers. |
Johnson & Johnson Pharmaceutical Research & Development |
| 20795648 |
27 |
Design, synthesis, and preliminary biological evaluation of new isoform-selective f-current blockers. |
Laboratory Of Design, Synthesis, And Study Of Biologically Active Heterocycles (Heterobiolab) |
Search and Browse
